Antitumor effect of forphenicinol, a low molecular weight immunomodifier, on murine transplantable tumors and microbial infections. 1982

M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa

The antitumor activities of forphenicinol against murine transplantable tumors were examined. Ehrlich carcinoma was suppressed by treatment with 0.08 approximately 0.31 mg/kg/day of forphenicinol given for 10 days starting 5 days after tumor inoculation. IMC carcinoma was also suppressed by treatment with 0.5 approximately 5 mg/kg/day given for 5 days starting 8 days after the inoculation. The antitumor activity was dependent on the number of tumor cells inoculated, schedule of administration and dose. However, even in case of fast growing tumors such as L1210 and inoculation with a large number of tumor cells, forphenicinol markedly enhanced the antitumor effect of 6-mercaptopurine, aclacinomycin and cyclophosphamide. Forphenicinol showed a protective effect on Pseudomonas infection in mice.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
February 1987, Journal of biological response modifiers,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
April 1986, The Journal of antibiotics,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
March 1985, Cancer treatment reports,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
April 1987, The Journal of antibiotics,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
October 1985, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
October 1978, Gan,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
August 1985, The Tohoku journal of experimental medicine,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
January 1984, Cancer treatment reports,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
January 1983, Nutrition and cancer,
M Ishizuka, and T Masuda, and N Kanbayashi, and Y Watanabe, and M Matsuzaki, and Y Sawazaki, and A Ohkura, and T Takeuchi, and H Umezawa
October 2007, The Journal of veterinary medical science,
Copied contents to your clipboard!